合計 50 件の最近のインサイダー取引記録が記録されています ANI Pharmaceuticals, Inc. (ANIP), 内訳は 9 件の買い および 41 件の売り. インサイダー買い総額は $14.28M インサイダー売り総額は $10.77M.
最近活動のある主要インサイダーには Mutz Christopher, Cook Meredith, Rowland Thomas Andrew. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — ANIP
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-03-13 |
Mutz Christopher |
Head of Rare Disease |
情報に基づく売り |
3,162 |
$71.64 |
$226.53K |
91,309 |
| 2026-03-13 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
情報に基づく売り |
500 |
$72.62 |
$36.31K |
79,390 |
| 2026-03-11 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
情報に基づく売り |
4,772 |
$74.91 |
$357.47K |
38,730 |
| 2026-03-09 |
Mutz Christopher |
Head of Rare Disease |
情報に基づく売り |
3,602 |
$74.18 |
$267.2K |
94,471 |
| 2026-03-09 |
Davis Krista |
SVP, Chief HR Officer |
情報に基づく売り |
5,087 |
$74.13 |
$377.1K |
51,946 |
| 2026-03-07 |
Carey Stephen P. |
SVP & CFO |
RSU 源泉徴収 |
5,150 |
$74.04 |
$381.31K |
180,393 |
| 2026-03-07 |
Lalwani Nikhil |
President & CEO |
RSU 源泉徴収 |
17,060 |
$74.04 |
$1.26M |
404,889 |
| 2026-03-07 |
Gutwerg Ori |
SVP, Generics |
RSU 源泉徴収 |
3,314 |
$74.04 |
$245.37K |
81,468 |
| 2026-03-07 |
Mutz Christopher |
Head of Rare Disease |
RSU 源泉徴収 |
3,314 |
$74.04 |
$245.37K |
98,073 |
| 2026-03-06 |
Mutz Christopher |
Head of Rare Disease |
情報に基づく売り |
2,121 |
$74.22 |
$157.42K |
101,387 |
| 2026-03-06 |
Davis Krista |
SVP, Chief HR Officer |
情報に基づく売り |
1,485 |
$75.00 |
$111.38K |
57,033 |
| 2026-03-05 |
Carey Stephen P. |
SVP & CFO |
オプション行使（売却） |
3,312 |
$49.51 |
$163.98K |
9,938 |
| 2026-03-03 |
Walsh Patrick D |
Director |
情報に基づく売り |
6,000 |
$74.23 |
$445.38K |
52,405 |
| 2026-03-03 |
Gutwerg Ori |
SVP, Generics |
情報に基づく売り |
2,060 |
$76.50 |
$157.59K |
84,782 |
| 2026-03-02 |
Mutz Christopher |
Head of Rare Disease |
情報に基づく売り |
417 |
$74.00 |
$30.86K |
103,508 |
| 2026-02-28 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
RSU 源泉徴収 |
628 |
$73.90 |
$46.41K |
43,502 |
| 2026-02-28 |
Carey Stephen P. |
SVP & CFO |
RSU 源泉徴収 |
2,773 |
$73.90 |
$204.92K |
189,543 |
| 2026-02-28 |
Lalwani Nikhil |
President & CEO |
RSU 源泉徴収 |
12,217 |
$73.90 |
$902.84K |
421,949 |
| 2026-02-28 |
Gutwerg Ori |
SVP, Generics |
RSU 源泉徴収 |
2,221 |
$73.90 |
$164.13K |
86,842 |
| 2026-02-28 |
Mutz Christopher |
Head of Rare Disease |
RSU 源泉徴収 |
2,221 |
$73.90 |
$164.13K |
103,925 |
| 2026-02-28 |
Gassert Chad |
SVP - Corp. Dev. & Strategy |
RSU 源泉徴収 |
2,221 |
$73.90 |
$164.13K |
74,916 |
| 2026-02-28 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
RSU 源泉徴収 |
1,555 |
$73.90 |
$114.91K |
79,890 |
| 2026-02-28 |
Davis Krista |
SVP, Chief HR Officer |
RSU 源泉徴収 |
1,555 |
$73.90 |
$114.91K |
58,518 |
| 2026-02-26 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
RSU 付与（制限付株式） |
6,021 |
$77.15 |
$464.52K |
44,130 |
| 2026-02-26 |
Carey Stephen P. |
SVP & CFO |
RSU 付与（制限付株式） |
22,233 |
$77.15 |
$1.72M |
192,316 |
| 2026-02-26 |
Lalwani Nikhil |
President & CEO |
RSU 付与（制限付株式） |
75,592 |
$77.15 |
$5.83M |
434,166 |
| 2026-02-26 |
Gutwerg Ori |
SVP, Generics |
RSU 付与（制限付株式） |
12,969 |
$77.15 |
$1M |
89,063 |
| 2026-02-26 |
Mutz Christopher |
Head of Rare Disease |
RSU 付与（制限付株式） |
21,306 |
$77.15 |
$1.64M |
106,146 |
| 2026-02-26 |
Shanmugam Muthusamy |
Head of R&d, COO-novitium Ops |
RSU 付与（制限付株式） |
11,116 |
$77.15 |
$857.6K |
101,056 |
| 2026-02-26 |
Gassert Chad |
SVP - Corp. Dev. & Strategy |
RSU 付与（制限付株式） |
11,116 |
$77.15 |
$857.6K |
77,137 |
| 2026-02-26 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
RSU 付与（制限付株式） |
13,895 |
$77.15 |
$1.07M |
81,445 |
| 2026-02-26 |
Davis Krista |
SVP, Chief HR Officer |
RSU 付与（制限付株式） |
10,810 |
$77.15 |
$833.99K |
60,073 |
| 2026-02-20 |
Mutz Christopher |
Head of Rare Disease |
情報に基づく売り |
5,323 |
$78.02 |
$415.3K |
84,840 |
| 2026-02-20 |
Davis Krista |
SVP, Chief HR Officer |
情報に基づく売り |
1,730 |
$77.99 |
$134.92K |
49,263 |
| 2026-02-19 |
Davis Krista |
SVP, Chief HR Officer |
情報に基づく売り |
2,084 |
$77.53 |
$161.57K |
50,993 |
| 2026-02-14 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
RSU 源泉徴収 |
485 |
$77.36 |
$37.52K |
38,109 |
| 2026-02-14 |
Carey Stephen P. |
SVP & CFO |
RSU 源泉徴収 |
2,448 |
$77.36 |
$189.38K |
170,083 |
| 2026-02-14 |
Lalwani Nikhil |
President & CEO |
RSU 源泉徴収 |
10,298 |
$77.36 |
$796.65K |
358,574 |
| 2026-02-14 |
Gutwerg Ori |
SVP, Generics |
RSU 源泉徴収 |
1,888 |
$77.36 |
$146.06K |
76,094 |
| 2026-02-14 |
Mutz Christopher |
Head of Rare Disease |
RSU 源泉徴収 |
2,403 |
$77.36 |
$185.9K |
90,163 |
| 2026-02-14 |
Gassert Chad |
SVP - Corp. Dev. & Strategy |
RSU 源泉徴収 |
1,717 |
$77.36 |
$132.83K |
66,021 |
| 2026-02-14 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
RSU 源泉徴収 |
1,779 |
$77.36 |
$137.62K |
67,550 |
| 2026-02-14 |
Davis Krista |
SVP, Chief HR Officer |
RSU 源泉徴収 |
1,290 |
$77.36 |
$99.79K |
53,077 |
| 2026-02-13 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
情報に基づく売り |
500 |
$76.80 |
$38.4K |
69,329 |
| 2026-02-12 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
RSU 源泉徴収 |
566 |
$76.70 |
$43.41K |
38,594 |
| 2026-02-12 |
Carey Stephen P. |
SVP & CFO |
RSU 源泉徴収 |
2,829 |
$76.70 |
$216.98K |
172,531 |
| 2026-02-12 |
Lalwani Nikhil |
President & CEO |
RSU 源泉徴収 |
11,688 |
$76.70 |
$896.47K |
368,872 |
| 2026-02-12 |
Gutwerg Ori |
SVP, Generics |
RSU 源泉徴収 |
1,775 |
$76.70 |
$136.14K |
77,982 |
| 2026-02-12 |
Mutz Christopher |
Head of Rare Disease |
情報に基づく売り |
7,032 |
$76.55 |
$538.3K |
92,566 |
| 2026-02-12 |
Gassert Chad |
SVP - Corp. Dev. & Strategy |
RSU 源泉徴収 |
1,608 |
$76.70 |
$123.33K |
67,738 |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
